Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES/FLOT7) with high rate of signet cell component: Final results of the multicenter, randomized phase II/III trial of the German AIO and Italian GOIM

Thorsten Oliver Goetze, Ralf-Dieter Hofheinz, Harald Schmalenberg, Dirk Strumberg, Eray Goekkurt, Stefan Angermeier, Thomas Zander, Jochem Potenberg, Hans-Georg Kopp, Daniel Pink, Gabriele Margareta Siegler, Michael Schenk, Ferdinando De Vita, Evaristo Maiello, Timo Gaiser, Disorn Sookthai, Tanita Brulin, Claudia Pauligk, Nils Homann, Salah-Eddin Al-Batran

Research output: Contribution to journalOriginal Articlepeer-review

2 Citations (Web of Science)
Original languageUndefined/Unknown
JournalJournal of Clinical Oncology
Publication statusPublished - 2022

Cite this